Robert Christenson

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, Maryland, USA
    MedGenMed 8:62. 2006
  2. ncbi Methodological and analytic considerations for blood biomarkers
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD, USA
    Prog Cardiovasc Dis 55:25-33. 2012
  3. ncbi Special section: utilization of B-type natriuretic peptide and N-terminal B-type natriuretic peptide in laboratory medicine. Foreword
    Robert Christenson
    University of Maryland, Clinical Chemistry Labs, Baltimore, MD 21201-1595, USA
    Clin Biochem 41:207. 2008
  4. ncbi Evidence-based laboratory medicine - a guide for critical evaluation of in vitro laboratory testing
    Robert H Christenson
    Laboratory of Pathology, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21085, USA
    Ann Clin Biochem 44:111-30. 2007
  5. ncbi What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care?
    Robert H Christenson
    Department of Pathology and Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem Lab Med 46:1524-32. 2008
  6. ncbi Stratus CS cardiac troponin I method: performance characteristics including imprecision at low concentrations
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Biochem 37:679-83. 2004
  7. ncbi Cardiac point of care testing: a focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Biochem 42:150-7. 2009
  8. ncbi Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Biochem 43:683-90. 2010
  9. ncbi Clinical performance characteristics of a new photometric lithium assay: a multicenter study
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chim Acta 327:157-64. 2003
  10. ncbi Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista® System
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Biochem 44:1128-36. 2011

Detail Information

Publications81

  1. ncbi Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, Maryland, USA
    MedGenMed 8:62. 2006
  2. ncbi Methodological and analytic considerations for blood biomarkers
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD, USA
    Prog Cardiovasc Dis 55:25-33. 2012
    ..In the absence of standardization, assays can be harmonized using secondary reference materials so that biomarker values can be combined for meta-analysis and interpreted clinically with common reference and decision limit values...
  3. ncbi Special section: utilization of B-type natriuretic peptide and N-terminal B-type natriuretic peptide in laboratory medicine. Foreword
    Robert Christenson
    University of Maryland, Clinical Chemistry Labs, Baltimore, MD 21201-1595, USA
    Clin Biochem 41:207. 2008
  4. ncbi Evidence-based laboratory medicine - a guide for critical evaluation of in vitro laboratory testing
    Robert H Christenson
    Laboratory of Pathology, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21085, USA
    Ann Clin Biochem 44:111-30. 2007
    ..Presenting the information appropriately maximizes clinical application of the best evidence...
  5. ncbi What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care?
    Robert H Christenson
    Department of Pathology and Medical and Research Technology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem Lab Med 46:1524-32. 2008
    ..Clinical use of these biomarkers in critically ill patients being treated in intensive care is not well established...
  6. ncbi Stratus CS cardiac troponin I method: performance characteristics including imprecision at low concentrations
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Biochem 37:679-83. 2004
    ..Define performance characteristics of the Stratus CS cardiac troponin I (cTnI) assay in routine practice...
  7. ncbi Cardiac point of care testing: a focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Biochem 42:150-7. 2009
    ..The National Academy for Clinical Biochemistry has recently developed practice guidelines for clinical, analytical and point-of-care (POC) testing in the context of ACS. Several technologies have become available for POC applications...
  8. ncbi Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Biochem 43:683-90. 2010
    ..Key analytical performance characteristics, the reference distribution and association of galectin-3 levels with clinical outcome in heart failure patients are defined...
  9. ncbi Clinical performance characteristics of a new photometric lithium assay: a multicenter study
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chim Acta 327:157-64. 2003
    ..We characterized a new photometric method that avoids the specialized requirements of ion-specific electrode (ISE), atomic absorption and flame emission methods...
  10. ncbi Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista® System
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Biochem 44:1128-36. 2011
    ..We examined analytical characteristics of new CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen (CEA), and Alpha-Fetoprotein (AFP) assays on the Dimension Vista® System...
  11. ncbi Laboratory medicine best practices: systematic evidence review and evaluation methods for quality improvement
    Robert H Christenson
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 57:816-25. 2011
    ..To develop methods for systematically reviewing evidence for identifying effective laboratory medicine (LM) practices associated with improved healthcare quality outcomes...
  12. ncbi Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 56:633-41. 2010
    ..Whether increased BMI affects accuracy of these biomarkers for diagnosing decompensated heart failure (HF) and predicting outcomes is unknown...
  13. ncbi Sensitive and high sensitivity next generation cardiac troponin assays: more than just a name
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD 21201, USA
    Pathology 43:213-9. 2011
    ....
  14. ncbi Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies
    R H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
    Cardiovasc Toxicol 1:171-6. 2001
    ..These data suggest that differences in reperfusion are reflected by kf and that this variable may represent a valuable new nonmortality end point derived from curve fitting analysis...
  15. ncbi N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis
    Christopher R DeFilippi
    Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    Am J Kidney Dis 46:35-44. 2005
    ..We sought to determine whether there is an association between NT-proBNP level and coronary artery disease (CAD) and left ventricular hypertrophy (LVH) in this population...
  16. ncbi N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients
    Ijaz A Khan
    Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Am J Cardiol 97:1530-4. 2006
    ..80, p = 0.001 for NT-pro-BNP; AUC 0.82, p = 0.0004 for BNP; p = 0.45 for NT-pro-BNP vs BNP). In conclusion, NT-pro-BNP and BNP levels are significant and equivalent indicators of CAD and LVH in asymptomatic patients with CKD...
  17. ncbi Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea
    Keyur B Shah
    The University of Maryland School of Medicine, Department of Medicine, Baltimore, MD, USA
    Clin Chem 55:59-67. 2009
    ..We sought to assess the diagnostic accuracy of MPO for acute decompensated heart failure (ADHF) and its prognostic value for patients with acute dyspnea...
  18. ncbi Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality
    Christopher R DeFilippi
    Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 53:1511-9. 2007
    ..We compared the accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) for diagnosing decompensated HF and predicting mortality across the spectrum of renal function...
  19. ncbi Cardiovascular disease testing on the Dimension Vista system: biomarkers of acute coronary syndromes
    Walter E Kelley
    Clinical Chemistry Labs, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Biochem 42:1444-51. 2009
    ..Performance characteristics of the LOCI cTnI, CK-MB, MYO, NTproBNP and hsCRP methods on the Dimension Vista System were evaluated...
  20. ncbi Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy)
    Robert H Christenson
    Pathology Department, University of Maryland Medical System, Baltimore, Maryland, USA
    Am J Cardiol 92:598-600. 2003
    ..These findings suggest that prodromal unstable angina is an important physiologic marker that should be routinely collected for risk stratification...
  21. ncbi Natriuretic peptides and echocardiography in acute dyspnoea: implication of elevated levels with normal systolic function
    Keyur B Shah
    Division of Cardiology, Department of Medicine, The University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Eur J Heart Fail 11:659-67. 2009
    ....
  22. ncbi Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays
    Robert H Christenson
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Clin Chem 52:1685-92. 2006
    ..The CIT cRM was selected by the AACC cTnI standardization committee, and a new lot has been classified as the cTnI certified reference material Standard Reference Material 2921 by NIST...
  23. ncbi Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting
    Robert S Poston
    Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Ann Thorac Surg 81:104-10; discussion 110-1. 2006
    ..In a randomized, prospective OPCABG trial, we assessed efficacy and safety of aprotinin through a comprehensive assessment of graft patency and hematologic function...
  24. ncbi B-type natriuretic peptide: physiologic role and assay characteristics
    Hassan M E Azzazy
    Departments of Pathology and Medical and Research Technology, University of Maryland School of Medicine, Baltimore, USA
    Heart Fail Rev 8:315-20. 2003
    ..The development of assays, including rapid point-of-care tests, has made BNP measurement a clinical reality...
  25. ncbi Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults
    Christopher R DeFilippi
    Department of Medicine, G3K63, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21212, USA
    JAMA 304:2494-502. 2010
    ..Older adults comprise the majority of new-onset heart failure (HF) diagnoses, but traditional risk-factor prediction models have limited accuracy in this population to identify those at highest risk for hospitalization or death...
  26. ncbi Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing
    Christopher R DeFilippi
    Division of Cardiology, Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Am Coll Cardiol 55:441-50. 2010
    ..This study sought to determine whether serial measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in community-dwelling elderly people would provide additional prognostic information to that from traditional risk factors...
  27. ncbi Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis
    Christopher deFilippi
    Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA
    JAMA 290:353-9. 2003
    ..However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear...
  28. ncbi B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures
    Jennifer A Taylor
    The University of Maryland School of Medicine and the Baltimore Veteran's Affairs Medical Center, Baltimore, MD, USA
    Am Heart J 152:1071-6. 2006
    ..The poor relationship between natriuretic peptide concentrations and LVEDP also suggests that these concentrations should not be considered surrogates for cardiac filling pressures or volumes...
  29. ncbi Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure
    Walter E Kelley
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Chem 55:2098-112. 2009
    ..This narrative review discusses increases in cTn that result from acute and chronic diseases, iatrogenic causes, and myocardial injury other than ACS and HF...
  30. ncbi Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay
    Kiang Teck J Yeo
    Department of Pathology, Dartmouth Medical School and Dartmouth Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, USA
    Clin Chim Acta 338:107-15. 2003
    ..Brain natriuretic peptides (BNPs) are useful in the assessment of heart failure, left ventricular dysfunction, and acute coronary syndromes...
  31. ncbi The characteristics and prognostic importance of NT-ProBNP concentrations in critically ill patients
    Keyur B Shah
    University of Maryland School of Medicine, Baltimore, USA
    Am J Med 120:1071-7. 2007
    ..We evaluate amino-terminal brain natriuretic peptide (NT-proBNP) in the medical ICU, specifically its correlation with noncardiac admission diagnosis and prognosis of critically ill patients...
  32. ncbi Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing?
    Hassan M E Azzazy
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Biochem 35:13-27. 2002
    ..We review whether cardiac marker testing performed at the point-of-care (POC) has an impact on clinical management and guidance of intervention for ACS patients...
  33. ncbi Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance
    Christopher R DeFilippi
    Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Am J Cardiol 100:885-9. 2007
    ....
  34. ncbi Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction
    Raymond D Bahr
    St. Agnes Hospital, Baltimore, Maryland, USA
    Am J Cardiol 90:310-2. 2002
  35. ncbi Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study
    Jeffrey C Fink
    Division of Nephrology, Department of Medicine, University of Maryland, Baltimore, MD, USA
    Am J Kidney Dis 39:1096-101. 2002
    ..Cohort studies in larger groups of transplant patients are needed to confirm a causal pathway between pretransplant inflammation, atherogenesis, and CAN...
  36. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure
    Robert H Christenson
    National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure, University of Maryland School of Medicine, Baltimore, MD, USA
    Clin Chem 53:545-6. 2007
  37. ncbi Two-center clinical evaluation of a new automated fluorometric immunoassay for the quantitative analysis of total betaeta-human chorionic gonadotropin
    Hassan M E Azzazy
    Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Clin Biochem 36:523-8. 2003
    ..0 IU/L for nonpregnant females (n = 120). CONCLUSIONS: The Stratus CS betahCG test offers the advantage of quantitative measurement of total betahCG in whole blood at the point of care and is suitable for clinical use...
  38. ncbi Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy)
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Baltimore, Maryland 21215, USA
    J Thromb Thrombolysis 14:213-9. 2002
    ..The effect of eptifibatide on these receptors was investigated in a substudy of the EARLY Trial...
  39. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, MN, USA
    Clin Biochem 41:222-6. 2008
  40. ncbi National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure
    Alan H B Wu
    University of California at San Francisco, San Francisco, CA, USA
    Clin Chem 53:2086-96. 2007
  41. ncbi Standardization of immunoassays for measurement of myoglobin in serum. Phase I: evaluation of candidate secondary reference materials
    Mauro Panteghini
    Laboratorio Analisi Chimico Cliniche 1, Azienda Ospedaliera Spedali Civili, 25125 Brescia, Italy
    Clin Chim Acta 341:65-72. 2004
    ..Its concentrations in serum can be measured by immunoassays and are used as an early indicator of myocardial necrosis. Since variability among commercial myoglobin assays exists, standardization of myoglobin assays is needed...
  42. ncbi Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial)
    Monica R Shah
    Washington Hospital Center, MedStar Research Institute, Washington, DC, USA
    Am J Cardiol 100:1427-33. 2007
    ..BNP decreased after hospitalization, but correlated modestly with PAC-derived hemodynamics. Rapid-assay BNP may provide information that helps physicians decide when to pursue more aggressive and invasive therapies...
  43. ncbi A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 146:993-8. 2003
    ..The acute benefits of platelet glycoprotein IIb/IIIa inhibitors for non-ST-segment elevation acute coronary syndromes (NSTE ACS) remain unclear...
  44. ncbi Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes
    Brett D Atwater
    University of Wisconsin Madison, Madison, Wisconsin, USA
    Am J Cardiol 100:1727-33. 2007
    ..In conclusion, more widespread measurement of BNP levels for risk stratification of patients with NSTE ACS may be warranted...
  45. ncbi Amino-terminal pro-B-type natriuretic peptide: analytic considerations
    Jordi Ordonez-Llanos
    Biochemistry Service, Hospital de la Santa Creu i Sant Pau, and the Department of Biochemistry and Molecular Biology, Universitat Autonoma, Barcelona, Spain
    Am J Cardiol 101:9-15. 2008
    ..When analyzed in patients with stable heart failure, biologic variability was 25%-40%. This article reviews the laboratory aspects of NT-proBNP testing from the perspective of the clinical laboratorian...
  46. ncbi Evaluation of imprecision for cardiac troponin assays at low-range concentrations
    Mauro Panteghini
    Laboratorio Analisi Chimico Cliniche 1, Azienda Ospedaliera Spedali Civili, 25125 Brescia, Italy
    Clin Chem 50:327-32. 2004
    ..Pools of human sera containing cardiac troponin concentrations around the MI decision limit were assessed to identify the lowest concentration associated with a 10% CV...
  47. ncbi Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage
    Kristin N Luckenbill
    Clin Chem 54:619-21. 2008
  48. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Cleveland Clinic, Foundation, Cleveland, OH, USA
    Clin Biochem 41:210-21. 2008
  49. ncbi Changing the model of care for patients with acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 146:605-12. 2003
    ..The shifting model of care for ACS therefore suggests that quality improvement and monitoring of adherence to practice guidelines should be considered components of optimal clinical practice...
  50. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, MN, USA
    Circulation 115:e352-5. 2007
  51. ncbi Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes
    Sunil V Rao
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Am J Cardiol 91:936-40. 2003
    ..This suggests that these patients should be admitted to the hospital and monitored in either an intensive care or step-down unit...
  52. ncbi Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative
    James W Hoekstra
    Ohio State University, Columbus, OH 43210, USA
    Acad Emerg Med 9:1146-55. 2002
    ..It is the intent of CRUSADE to improve patient care in the ED by tracking and encouraging compliance with evidence-based guidelines for the evaluation and management of NSTE ACS...
  53. ncbi Prognostic significance of elevated troponin I after percutaneous coronary intervention
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada M5B 1W8
    J Am Coll Cardiol 39:1738-44. 2002
    ..We sought to assess the incidence and clinical significance of elevated cardiac troponin I (cTnI) after percutaneous coronary intervention (PCI)...
  54. ncbi Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study)
    David E Kandzari
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 93:636-9. 2004
    ..5 degrees C) and was well tolerated, which supports the evaluation of adjunctive hypothermia in pivotal trials to limit infarct size and decrease reperfusion injury...
  55. ncbi Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes
    L Kristin Newby
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715 7969, USA
    J Am Coll Cardiol 47:312-8. 2006
    ..We sought to evaluate the association between discordant cardiac marker results and in-hospital mortality and treatment patterns in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  56. ncbi Influence of imprecision on ROC curve analysis for cardiac markers
    Peter Kupchak
    Nanogen, Point of Care Diagnostics Division, Toronto, Ontario, Canada
    Clin Chem 52:752-3. 2006
    ..CONCLUSION: Assay imprecision does not appear to be a critical determinant in the interpretation of cardiac marker results for patients with heart disease...
  57. ncbi Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Ann Emerg Med 45:355-62. 2005
    ....
  58. ncbi Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Clinical Laboratories, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Clin Chem 51:810-24. 2005
    ....
  59. ncbi Quality specifications for B-type natriuretic peptide assays
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN 55415, USA
    Clin Chem 51:486-93. 2005
    ....
  60. ncbi Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department
    Frank Peacock
    Department of Emergency Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:253-62. 2006
    ..4% and 97.1% and, for longer-term outcomes, were 89.2% and 94.5%, respectively. CONCLUSIONS: A negative TPT of a nondiagnostic electrocardiogram, negative troponin, and negative IMA has a high NPV for excluding ACS in the ED...
  61. ncbi Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction
    Alan H B Wu
    Department of Pathology and Laboratory Medicine, Hartford Hospital, 80 Seymour St, Hartford, CT 06102, USA
    Clin Chim Acta 346:211-9. 2004
    ..With new rapid ED assessment protocols, there is increasing pressure to produce results with a short turnaround time (TAT), and point-of-care (POC) testing is one alternative for providing fast results...
  62. ncbi Delta creatine kinase-MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non-ST-segment elevation acute coronary syndromes
    Francis M Fesmire
    Heart and Stroke Center, University of Tennessee College of Medicine, Chattanooga, TN 37405, USA
    Ann Emerg Med 44:12-9. 2004
    ..This finding suggests that myoglobin may no longer be the optimal early marker of acute myocardial infarction when troponins are used as the criterion standard...
  63. ncbi Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications
    Hassan M E Azzazy
    Department of Chemistry and Science and Technology Research Center, School of Science and Engineering, The American University in Cairo, Cairo, Egypt
    Clin Chem 52:19-29. 2006
    ..Unbound free fatty acids (FFA(u)) and their intracellular binding protein, heart-type fatty acid-binding protein (H-FABP), have been suggested to have clinical utility as indicators of cardiac ischemia and necrosis, respectively...
  64. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Clin Chem 53:552-74. 2007
  65. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Brigham and Women's Hospital, Harvard University, Boston, MA, USA
    Circulation 115:e356-75. 2007
  66. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, Minn, USA
    Circulation 116:e95-8. 2007
  67. ncbi Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction
    Fred S Apple
    Hennepin County Medical Center and University of Minnesota School of Medicine, Minneapolis, 55415, USA
    Clin Chem 51:2198-200. 2005
  68. ncbi National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Circulation 116:e99-109. 2007
  69. ncbi Analytical performance of the i-STAT cardiac troponin I assay
    Fred S Apple
    Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota School of Medicine, Clinical Labs P4, 701 Park Avenue, Minneapolis, MN 55415, USA
    Clin Chim Acta 345:123-7. 2004
    ..This study determines the analytical characteristics of the i-STAT cardiac troponin I assay (cTnI; i-STAT, Princeton, NJ), a 10-min POC assay, designed to be performed at the bedside...
  70. ncbi Biomarkers of ischemia in patients with known coronary artery disease: do interleukin-6 and tissue factor measurements during dobutamine stress echocardiography give additional insight?
    Robert H Christenson
    Circulation 112:3215-7. 2005
  71. ncbi Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ..4 vs. 1.5). CONCLUSIONS: Quantitative ST and cTnT status are complementary in assessing risk among ACS patients and both should be employed to determine prognosis and assist in medical decision making...
  72. ncbi Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Arch Intern Med 165:1870-6. 2005
    ..The threshold of troponin elevation that stimulates changes in clinical decision making for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACSs) has not been previously evaluated...
  73. ncbi Intra- and interindividual variations in urinary concentrations of endogenous gamma-hydroxybutyrate
    Marc A LeBeau
    Chemistry Unit, FBI Laboratory, Federal Bureau of Investigation, Washington, DC 20535, USA
    J Anal Toxicol 26:340-6. 2002
    ..Patients with such a deficiency should be readily identifiable through prominent symptoms, repeated urinalysis, or genetic testing...
  74. ncbi Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems
    Hassan M E Azzazy
    Clin Chim Acta 384:176-8. 2007
  75. ncbi Do glycoprotein IIb/IIIa inhibitors interact with assays for myocardial necrosis?
    Warren J Cantor
    Department of Medicine, St Michael s Hospital, Toronto, Ontario, Canada
    Clin Biochem 36:663-6. 2003
    ..To determine whether glycoprotein (GP) IIB/IIIA inhibitors interact with cardiac marker assays: total creatine kinase (CK), CK-MB, and troponin-I (TnI)...
  76. ncbi Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cardiol 31:125-9. 2008
    ..The prognostic value of cardiac troponins (cTn) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and chronic kidney disease (CKD) is debated...
  77. ncbi Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative
    E Magnus Ohman
    Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Am Heart J 148:S34-9. 2004
    ..These ACC/AHA guidelines are intended to help physicians make appropriate decisions when diagnosing and treating patients with NSTE ACS...
  78. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Clin Chem 53:547-51. 2007
  79. ncbi The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 151:1205-13. 2006
    ..We characterized guideline adherence for NSTE ACS by risk status...
  80. ncbi Preamble: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for utilization of biomarkers in acute coronary syndromes and heart failure
    Robert H Christenson
    Clin Biochem 41:208-9. 2008
  81. ncbi Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the
    Russell V Luepker
    Circulation 108:2543-9. 2003